Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia.

CML GEF RAC RAS SOS-KO phenotypes SOS1 SOS2 myeloproliferative disorders

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 Aug 2022
Historique:
received: 19 07 2022
revised: 09 08 2022
accepted: 10 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

We showed previously that the ABL-mediated phosphorylation of SOS1 promotes RAC activation and contributes to BCR-ABL leukemogenesis, suggesting the relevant role of SOS1 in the pathogenesis of CML. To try and obtain direct experimental evidence of the specific mechanistic implication of SOS1 in CML development, here, we combined a murine model of CML driven by a p210

Identifiants

pubmed: 36010887
pii: cancers14163893
doi: 10.3390/cancers14163893
pmc: PMC9406065
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Instituto de Salud Carlos III
ID : FIS PI19/00934
Organisme : Junta de Castilla y León
ID : SA264P18-UIC 076
Organisme : Fundación Ramón Areces
ID : CIVP19A5942
Organisme : Solorzano-Barruso Foundation
ID : FS/32-2020
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00352

Références

Stem Cell Res Ther. 2021 Dec 18;12(1):603
pubmed: 34922630
Nat Cell Biol. 2004 Mar;6(3):268-74
pubmed: 15039778
Mol Cell Biol. 2018 Jul 30;38(16):
pubmed: 29844066
Oncogene. 1993 Feb;8(2):467-77
pubmed: 8381222
Int J Mol Sci. 2021 Jun 30;22(13):
pubmed: 34209376
Acta Haematol. 2014;132(2):166-71
pubmed: 24577437
Blood. 2018 Dec 13;132(24):2575-2579
pubmed: 30377195
Mol Cell Biol. 2000 Sep;20(17):6410-3
pubmed: 10938118
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11858-62
pubmed: 9751755
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Mol Cell Biol. 2005 Jul;25(13):5777-85
pubmed: 15964830
Nat Commun. 2021 Mar 12;12(1):1661
pubmed: 33712601
Leukemia. 2012 May;26(5):1030-7
pubmed: 22193968
Nat Med. 2017 Apr;23(4):472-482
pubmed: 28319094
Genome Biol. 2021 Dec 20;22(1):343
pubmed: 34930405
Sci Signal. 2018 Oct 30;11(554):
pubmed: 30377222
Science. 1987 Jul 31;237(4814):532-5
pubmed: 2440107
Cancer Discov. 2022 Apr 1;12(4):924-937
pubmed: 35046095
Mol Cell Biol. 2013 Nov;33(22):4562-78
pubmed: 24043312
Leukemia. 2008 May;22(5):898-904
pubmed: 18354486
J Leukoc Biol. 2019 Oct;106(4):815-822
pubmed: 30720883
Exp Hematol. 2022 Apr;108:26-35
pubmed: 35181392
Oncogene. 2016 Dec 15;35(50):6389-6402
pubmed: 27157612
Cancer Cell. 2020 Apr 13;37(4):530-542
pubmed: 32289275
Oncogene. 2021 Jul;40(27):4538-4551
pubmed: 34120142
Leukemia. 2018 Mar;32(3):820-827
pubmed: 28819285
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560
pubmed: 30683722
Med Oncol. 2021 Jan 16;38(1):10
pubmed: 33452624
Asian Pac J Cancer Prev. 2015;16(17):7415-23
pubmed: 26625737
J Natl Cancer Inst. 1960 Jul;25:85-109
pubmed: 14427847
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Cell Death Dis. 2019 Aug 13;10(8):617
pubmed: 31409768
Mol Ther Oncolytics. 2021 Nov 20;23:560-570
pubmed: 34938856
Nat Med. 2017 Oct;23(10):1234-1240
pubmed: 28920959
Blood Cells Mol Dis. 2001 Jan-Feb;27(1):265-78
pubmed: 11358387
Leuk Lymphoma. 1995 Jan;16(3-4):297-305
pubmed: 7536510
Cancer Cell. 2007 Nov;12(5):467-78
pubmed: 17996650
Caspian J Intern Med. 2018 Winter;9(1):65-70
pubmed: 29387322
EMBO J. 2000 Feb 15;19(4):642-54
pubmed: 10675333
Blood. 1998 Mar 15;91(6):2067-75
pubmed: 9490692
Int J Mol Sci. 2021 Nov 19;22(22):
pubmed: 34830398
Nat Genet. 2016 Dec;48(12):1551-1556
pubmed: 27798625
Ther Adv Hematol. 2015 Dec;6(6):308-12
pubmed: 26622999
Cancers (Basel). 2022 Jan 05;14(1):
pubmed: 35008420
Cancer Discov. 2021 Jan;11(1):142-157
pubmed: 32816843
Neuroscience. 2007 Apr 25;146(1):272-85
pubmed: 17321057
Nat Commun. 2012;3:1168
pubmed: 23132018
Cancers (Basel). 2021 Apr 29;13(9):
pubmed: 33946974
Blood. 1996 Oct 1;88(7):2410-4
pubmed: 8839830
Oncogene. 2004 Jun 17;23(28):4885-93
pubmed: 15077165
Drug Des Devel Ther. 2019 Mar 08;13:825-843
pubmed: 30880916
Exp Cell Res. 2006 Apr 1;312(6):938-48
pubmed: 16443220
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188445
pubmed: 33035641
Leukemia. 2022 Jan;36(1):1-12
pubmed: 34561557
Oncogenesis. 2019 Jan 4;8(1):2
pubmed: 30631038
Biomolecules. 2021 Jul 30;11(8):
pubmed: 34439794
Blood. 2002 Jul 1;100(1):238-45
pubmed: 12070033

Auteurs

Carmela Gómez (C)

Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca and CIBERONC, 37007 Salamanca, Spain.

Rósula Garcia-Navas (R)

Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca and CIBERONC, 37007 Salamanca, Spain.

Fernando C Baltanás (FC)

Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca and CIBERONC, 37007 Salamanca, Spain.
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, 41013 Seville, Spain.
Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41013 Seville, Spain.

Rocío Fuentes-Mateos (R)

Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca and CIBERONC, 37007 Salamanca, Spain.

Alberto Fernández-Medarde (A)

Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca and CIBERONC, 37007 Salamanca, Spain.

Nuria Calzada (N)

Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca and CIBERONC, 37007 Salamanca, Spain.

Eugenio Santos (E)

Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca and CIBERONC, 37007 Salamanca, Spain.

Classifications MeSH